Objective: To estimate whether the topical debriding agent, Debrichem, could potentially afford the UK’s National Health Service (NHS) a cost-effective intervention for the management of
All testing was performed in triplicate and testing was completed twice, separated by 2 weeks apart. This was to ensure reproducibility (Parker et al., 2018).
“If biofilms keep chronic wounds from healing, then Debrichem® is the solution” It is with great pride and anticipation that Debx Africa (Pty) Ltd are
This licence authorises manufacture by the licence holder named; if the business should change hands, the company or person taking over the business will have
The licence holder and the persons described and named in Annexure 1 shall at all times ensure that all medical devices distributed, irrespective of its
